Paladin Labs Announces the Canadian Launch of Veregen®

 MONTREAL, July 16, 2014 /CNW/ -- Paladin Labs Inc., a subsidiary of Endo  International plc (Nasdaq: ENDP) (TSX: ENL) and a leading Canadian specialty  pharmaceutical company, today announced the launch of Veregen®  (sinecatechins) Ointment, 10%, a topical treatment for external genital and  perianal warts (condylomata acuminata) in immunocompetent patients aged 18  years and over.  Clinically visible warts are present in approximately 1% of sexually active  adults, making genital warts the most common sexually transmitted  infection(1).  Studies have demonstrated that for individuals with external  genital warts, the reduction in their quality of life is of similar magnitude  to that seen in people with moderate to severe asthma or osteoarthritis(2).  "We are pleased to announce the launch of Veregen® in Canada," said Mark  Beaudet, President of Paladin Labs Inc. "Sexually transmitted infections  (STIs) such as external genital warts can cause tremendous psychological  stress(3).  Canadians who suffer from external genital warts now have a new,  non-invasive and effective topical treatment option with a demonstrated  tolerability profile."  Paladin obtained the exclusive rights to market Veregen® in Canada from  Medigene AG in May 2014.  About Veregen: Veregen® (sinecatechins) Ointment 10% is a topical treatment  for external genital and perianal warts (condylomata acuminata) in  immunocompetent patients aged 18 years and over.  It is available in a 15g  tube.  The drug substance in Veregen® is sinecatechins, which is a partially  purified fraction of the water extract of green tea leaves from Camellia  sinensis (L.) O Kuntze and is a mixture of catechins and other green tea  components.  The most common side effects with Veregen® Ointment are local  skin and application site reactions, but these should decrease over time(4).  Sinecatechins 10% & 15% Ointment (Veregen®) has been included in the 2012  European Guideline for the Management of Anogenital Warts.  In addition, in  its current treatment guidelines for sexually transmitted diseases, the US  Center for Disease Control and Prevention recommends Sinecatechins 15%  Ointment (Veregen®) as a possible option for treating genital warts.  About Paladin Labs Inc.: Paladin Labs Inc., headquartered in Montreal, Canada,  is a specialty pharmaceutical company focused on acquiring or in-licensing  innovative pharmaceutical products for Canadian and select emerging markets.  Paladin has a focused marketing and sales organization that has helped it  evolve into one of Canada's leading specialty pharmaceutical companies.  Paladin is an operating company of Endo International plc, a global specialty  healthcare company focused on improving patients' lives while creating  shareholder value.  Learn more at  1. Society of Obstetricians and Gynaecologists of Canada. Canadian   consensus guidelines on human papillomavirus. J Obstet Gynaecol   Can 2007;29(8 Suppl 3):S1-56.   2. F. Marra, G. Ogilivie, L. Colley, E. Kliewer, C.A. Marra.   Epidemiology and costs associated with genital warts in Canada.   Sex Transfm Infect 2009;85:111 - 115.   3. G. Mortenson, H. Larsen. The quality of life of patients with   genital warts: a qualitative study. BMC Public Health 2010,   10:113.   4. Veregen® Product Monograph. Triton Pharma Inc., August 27, 2013.  Forward-Looking Statements  Cautionary Note Regarding Forward-Looking Statements  This press release contains forward-looking statements within the meaning of  the Private Securities Litigation Reform Act of 1995 and Canadian securities  legislation. Statements including words such as "believes," "expects,"  "anticipates," "intends," "estimates," "plan," "will," "may," "look forward,"  "intend," "guidance," "future" or similar expressions are forward-looking  statements. Because these statements reflect Endo's current views,  expectations and beliefs concerning future events, these forward-looking  statements involve risks and uncertainties. Although Endo believe that these  forward-looking statements and information are based upon reasonable  assumptions and expectations, readers should not place undue reliance on them,  or any other forward-looking statements or information in this news release.  Investors should note that many factors, as more fully described in the  documents filed by Endo and Endo Health Solutions Inc. ("EHSI") with  securities regulators in the United States and Canada including under the  caption "Risk Factors" in EHSI's Form 10-K, and Endo's Form 10-Q and Form 8-K  filings, as applicable, with the Securities and Exchange Commission and by  Endo with securities regulators in Canada on the System for Electronic  Document Analysis and Retrieval ("SEDAR") and as otherwise enumerated herein  or therein, could affect Endo's future financial results and could cause  Endo's actual results to differ materially from those expressed in  forward-looking statements contained in EHSI's Annual Report on Form 10-K. The  forward-looking statements in this press release are qualified by these risk  factors. These are factors that, individually or in the aggregate, could cause  Endo's actual results to differ materially from expected and historical  results. Endo does not assume any obligation to publicly update any  forward-looking statements, whether as a result of new information, future  developments or otherwise, except as may be required under applicable  securities law.    SOURCE  Endo International plc  Investors/Media: Blaine Davis, +353-1-669-6635, (484) 216-7158; Investors:  Jonathan Neely, (484) 216-6645; Media: Brian O'Donnell, (484) 216-6726  CO: Paladin Labs Inc. ST: Quebec NI: MTC HEA NP  
Press spacebar to pause and continue. Press esc to stop.